Published in Am J Respir Crit Care Med on December 12, 2008
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax (2012) 4.06
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med (2010) 2.85
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J (2011) 1.68
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort study. BMC Pulm Med (2011) 1.22
Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One (2012) 1.15
Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med (2013) 1.14
Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis (2011) 1.05
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open (2014) 1.02
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Variations in the management of acute exacerbations of chronic obstructive pulmonary disease. Can Respir J (2013) 0.96
Missing potential opportunities to reduce repeat COPD exacerbations. J Gen Intern Med (2012) 0.93
Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study. PLoS One (2014) 0.88
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis (2011) 0.87
Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcomes (2013) 0.86
PROLONG: a cluster controlled trial to examine identification of patients with COPD with poor prognosis and implementation of proactive palliative care. BMC Pulm Med (2014) 0.85
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.85
Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser (2012) 0.85
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2016) 0.85
Predictors of exacerbation frequency in chronic obstructive pulmonary disease. Eur J Med Res (2014) 0.84
Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation. Int J Chron Obstruct Pulmon Dis (2013) 0.84
Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.83
Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med (2014) 0.83
Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med (2014) 0.82
The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.81
Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis (2014) 0.81
How do COPD patients respond to exacerbations? BMC Pulm Med (2011) 0.80
Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. PLoS One (2016) 0.79
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
Patient-Centered Medical Home in chronic obstructive pulmonary disease. J Multidiscip Healthc (2011) 0.79
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med (2016) 0.79
Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respir Res (2014) 0.78
Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser (2012) 0.78
Heterogeneity's ruses: the neglected role of between-individual variability in longitudinal studies of COPD exacerbations. Thorax (2014) 0.78
Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians. Int J Gen Med (2011) 0.76
Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD. Int J Chron Obstruct Pulmon Dis (2015) 0.76
COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future. Multidiscip Respir Med (2010) 0.75
C-reactive protein in outpatients with acute exacerbation of COPD: its relationship with microbial etiology and severity. Int J Chron Obstruct Pulmon Dis (2016) 0.75
"Temporal clustering" of COPD exacerbations may reflect corticosteroid withdrawal. Am J Respir Crit Care Med (2009) 0.75
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. J Aerosol Med Pulm Drug Deliv (2016) 0.75
Temporal clustering of exacerbations of COPD: not-so-surprising findings. Am J Respir Crit Care Med (2009) 0.75
The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. Am J Epidemiol (2016) 0.75
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation. Am Health Drug Benefits (2016) 0.75
Exacerbations of chronic obstructive pulmonary disease. Open Nurs J (2012) 0.75
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Acute exacerbation of COPD: is it the "stroke of the lungs"? Int J Chron Obstruct Pulmon Dis (2016) 0.75
The role of complement activation in COPD exacerbation recovery. ERJ Open Res (2016) 0.75
Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Frequent exacerbators in COPD: who are they? Am J Respir Crit Care Med (2009) 0.75
The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD. Thorax (2017) 0.75
Self-management behaviors to reduce exacerbation impact in COPD patients: a Delphi study. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16
Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J (2010) 2.14
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Exacerbations of chronic obstructive pulmonary disease. Respir Care (2003) 1.80
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.73
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev (2012) 1.60
C-reactive protein: does it predict mortality? Am J Respir Crit Care Med (2007) 1.47
Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One (2013) 1.43
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Outdoor air pollution and respiratory health in patients with COPD. Thorax (2011) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One (2011) 1.37
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med (2012) 1.26
Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J (2008) 1.26
A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health (2004) 1.17
Controversies in treatment of chronic obstructive pulmonary disease. Lancet (2011) 1.16
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.10
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest (2005) 1.07
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res (2007) 0.98
Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD (2007) 0.95
Viral infections in obstructive airway diseases. Curr Opin Pulm Med (2003) 0.93
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med (2004) 0.92
Reduced lung-cancer mortality with CT screening. N Engl J Med (2011) 0.89
Natural history of successive COPD exacerbations. Thorax (2012) 0.87
Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res (2014) 0.86
Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med (2015) 0.86
Stakeholder involvement: how to do it right: article 9 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.86
The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med (2007) 0.84
Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim Care Respir J (2013) 0.84
The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med (2010) 0.84
Relationship between chronic nasal and respiratory symptoms in patients with COPD. Respir Med (2003) 0.84
Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med (2014) 0.83
Deprivation, winter season, and COPD exacerbations. Prim Care Respir J (2013) 0.81
Choice of bronchodilator therapy for patients with COPD. N Engl J Med (2011) 0.81
Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. Eur Respir J (2012) 0.80
Exacerbation of chronic obstructive pulmonary disease: pan-airway and systemic inflammatory indices. Proc Am Thorac Soc (2006) 0.79
Winter mortality in elderly people in Britain: action on outdoor cold stress is needed to reduce winter mortality. BMJ (2004) 0.78